THE RESULTS OF CLINICAL RESEARCHES: THE STUDY OF CYTOPROTECTIVE PROPERTIES (CHEMO/ RADIOPROTECTIVE) OF FLAMENA 100 ML ORAL EMULSION AT PACIENTS DIAGNOSED WITH BREAST CANCER AND REPRODUCTIVE ORGANS WHO UNDERGO CHEMOOR RADIOTHERAPY Summary: It is studied the Flamen indigenous combined medical substance 100 ml oral emulsion containing the active ingredients glycine and dihidroquercitina. In General Oncology Clinic and the IP Mammology Medical University “Nicolae Testemitanu” clinical trial was conducted according to the principles of good practice in research involving breast cancer and cancer of the reproductive organs. It was determined that 100ml of Flamen is harmless, easy to administer and is recommended for those suffering from malignancies as adjuvant radiotherapy after polichymioterapy. It is considered to have antyoxydant effects, liver, immune stimulator and detoxifier.